Literature DB >> 7858910

The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis.

T M Forte1, M R McCall.   

Abstract

The inverse relationship between HDL and apolipoprotein A-I concentrations and the risk for premature atherosclerosis is well established, but the mechanism whereby apolipoprotein A-I offers protection is still somewhat elusive. Recent studies suggest that a specific subpopulation within the lipoprotein (AI) subclass may be more effective than others in promoting cholesterol efflux from cells. In addition, it appears that the lipid-free form of apolipoprotein A-I may have an important role in the antiatherosclerotic process. Unique new functions of apolipoprotein A-I-containing particles in modulating cytokines and lipid hydroperoxide transport, together with their role in antiatherogenesis, are also discussed. Current research with transgenic mice, however, indicates that apolipoprotein A-II must be taken into consideration in understanding the development of atherosclerosis, because it appears to be a potent antagonist for the protective properties of apolipoprotein A-I.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858910     DOI: 10.1097/00041433-199410000-00007

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  11 in total

Review 1.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Apolipoproteins AI/B/E gene polymorphism and their plasma levels in patients with coronary artery disease in a tertiary care-center of Eastern India.

Authors:  Santanu Biswas; Pradip K Ghoshal; Bhubaneswar Halder; Kajal Ganguly; Arup DasBiswas; Nripendranath Mandal
Journal:  Indian Heart J       Date:  2013-10-30

3.  BMP1 5'UTR + 104 T/C gene variation: can be a predictive marker for serum HDL and apoprotein A1 levels in male patients with coronary heart disease.

Authors:  Basak Akadam-Teker; Gulcin Ozkara; Ozlem Kurnaz-Gomleksiz; Zehra Bugra; Erhan Teker; Oguz Ozturk; Hulya Yilmaz-Aydogan
Journal:  Mol Biol Rep       Date:  2018-07-30       Impact factor: 2.316

Review 4.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

5.  Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.

Authors:  San-Chiang Wu; Jeng-Chuan Shiang; Shoa-Lin Lin; Te-Lang Wu; Wei-Chun Huang; Kuan-Rau Chiou; Chun-Peng Liu
Journal:  Heart Vessels       Date:  2005-09       Impact factor: 2.037

6.  Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease.

Authors:  X L Wang; S X Liu; R M McCredie; D E Wilcken
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

7.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.

Authors:  L Lindstedt; M Lee; G R Castro; J C Fruchart; P T Kovanen
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

9.  Plasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathway.

Authors:  Trayambak Basak; Vinay Singh Tanwar; Gourav Bhardwaj; Nitin Bhardwaj; Shadab Ahmad; Gaurav Garg; Sreenivas V; Ganesan Karthikeyan; Sandeep Seth; Shantanu Sengupta
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

10.  Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter?

Authors:  Sedigheh Asgary; Nizal Sarrafzadegan; Gholam-Ali Naderi; Reza Rozbehani
Journal:  Lipids Health Dis       Date:  2008-11-03       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.